DIPG Abstract 2011

  1. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.
    Sethi R, Allen J, Donahue B, Karajannis M, Gardner S, Wisoff J, Kunnakkat S, Mathew J, Zagzag D, Newman K, Narayana A
    J Neurooncol. 2011 Mar;102(1):121-7. Epub 2010 Jul 10.
    http://www.ncbi.nlm.nih.gov/pubmed/20623246

  2. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.
    Wolff JE, Kortmann RD, Wolff B, Pietsch T, Peters O, Schmid HJ, Rutkowski S, Warmuth-Metz M, Kramm C.
    J Neurooncol. 2011 May;102(3):433-42. Epub 2010 Aug 8.
    http://www.ncbi.nlm.nih.gov/pubmed/20694800

  3. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
    Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium.
    Neuro Oncol. 2011 Jan;13(1):109-18. Epub 2010 Oct 25.
    http://www.ncbi.nlm.nih.gov/pubmed/20974795

  4. DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
    Prabhu SP, Ng S, Vajapeyam S, Kieran MW, Pollack IF, Geyer R, Haas-Kogan D, Boyett JM, Kun L, Poussaint TY.
    Childs Nerv Syst. 2011 Jan;27(1):11-8. Epub 2010 Nov 4.
    http://www.ncbi.nlm.nih.gov/pubmed/21052693

  5. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma.
    Löbel U, Sedlacik J, Reddick WE, Kocak M, Ji Q, Broniscer A, Hillenbrand CM, Patay Z.
    AJNR Am J Neuroradiol. 2011 Feb;32(2):315-22. Epub 2010 Nov 18
    http://www.ncbi.nlm.nih.gov/pubmed/21087935

  6. Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
    Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle B, Grundy R.
    Neuro Oncol. 2011 Feb;13(2):212-22. Epub 2010 Dec 7.
    http://www.ncbi.nlm.nih.gov/pubmed/21138945

  7. Monitoring of tumor growth and post-irradiation recurrence in a diffuse intrinsic pontine glioma mouse model.
    Caretti V, Zondervan I, Meijer DH, Idema S, Vos W, Hamans B, Bugiani M, Hulleman E, Wesseling P, Vandertop WP, Noske DP, Kaspers G, Molthoff CF, Wurdinger T.
    Brain Pathol. 2011 Jul;21(4):441-51. doi: 10.1111/j.1750-3639.2010.00468.x. Epub 2010 Dec 29.
    http://www.ncbi.nlm.nih.gov/pubmed/21159008

  8. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.
    Massimino M, Bode U, Biassoni V, Fleischhack G.
    Expert Opin Biol Ther. 2011 Feb;11(2):247-56. Epub 2010 Dec 21
    http://www.ncbi.nlm.nih.gov/pubmed/21171927

  9. Role of adaptive radiation therapy for pediatric patients with diffuse pontine glioma.
    Beltran C, Sharma S, Merchant TE.
    J Appl Clin Med Phys. 2011 Jan 30;12(2):3421.
    http://www.ncbi.nlm.nih.gov/pubmed/21587190

  10. Palliative Reirradiation for Progressive Diffuse Intrinsic Pontine Glioma.
    Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, Wolff JE, Mahajan A.
    Am J Clin Oncol. 2011 Feb 3. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/21297433

  11. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
    Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR.
    Neuro Oncol. 2011 Mar;13(3):290-7. Epub 2011 Feb 3.
    http://www.ncbi.nlm.nih.gov/pubmed/21292687

  12. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
    Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson L, Geyer R, Haas-Kogan D, Pollack IF, Vezina G, Zimmerman R, Cha S, Patay Z, Boyett JM, Kun LE.
    Neuro Oncol. 2011 Apr;13(4):417-27. Epub 2011 Feb 4.
    http://www.ncbi.nlm.nih.gov/pubmed/21297126

  13. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution’s experience.
    Negretti L, Bouchireb K, Levy-Piedbois C, Habrand JL, Dhermain F, Kalifa C, Grill J, Dufour C.
    J Neurooncol. 2011 Sep;104(3):773-7. Epub 2011 Feb 17.
    http://www.ncbi.nlm.nih.gov/pubmed/21327862

  14. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group.
    Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF.
    Neuro Oncol. 2011 Apr;13(4):410-6. Epub 2011 Feb 22.
    http://www.ncbi.nlm.nih.gov/pubmed/21345842

  15. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.
    Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, Fisher PG, Weissman IL, Rowitch DH, Vogel H, Wong AJ, Beachy PA.
    Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4453-8. Epub 2011 Mar 1.

  16. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
    Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE.
    Neuro Oncol. 2011 Mar;13(3):298-306.
    http://www.ncbi.nlm.nih.gov/pubmed/21339191

  17. Diffuse intrinsic brainstem tumor in an infant: a case of therapeutic efficacy with vinorelbine.
    Cappellano AM, Bouffet E, Cavalheiro S, Seixas MT, da Silva NS.
    J Pediatr Hematol Oncol. 2011 Mar;33(2):116-8.
    http://www.ncbi.nlm.nih.gov/pubmed/21228720

  18. Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma.
    Mateos ME, López-Laso E, Izquierdo L, Pérez-Navero JL, García S, Garzás C.
    Pediatr Int. 2011 Apr;53(2):261-3. doi: 10.1111/j.1442-200X.2010.03220.x.
    http://www.ncbi.nlm.nih.gov/pubmed/21501315

  19. Diffuse intrinsic pontine glioma-current status and future strategies.
    Khatua S, Moore KR, Vats TS, Kestle JR.
    Childs Nerv Syst. 2011 Sep;27(9):1391-7. Epub 2011 Apr 30.
    http://www.ncbi.nlm.nih.gov/pubmed/21533575

  20. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma.
    Yamasaki F, Kurisu K, Kajiwara Y, Watanabe Y, Takayasu T, Akiyama Y, Saito T, Hanaya R, Sugiyama K.
    Neuro Oncol. 2011 Jul;13(7):791-801. Epub 2011 Jun 8.
    http://www.ncbi.nlm.nih.gov/pubmed/21653595

  21. Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study.
    Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB.
    Pediatr Hematol Oncol. 2011 Oct;28(7):556-70. Epub 2011 Jun 24.
    http://www.ncbi.nlm.nih.gov/pubmed/21699466

  22. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons.
    Hankinson TC, Campagna EJ, Foreman NK, Handler MH.
    J Neurosurg Pediatr 2011 Jul;8(1):97-102.
    http://www.ncbi.nlm.nih.gov/pubmed/21721895

  23. Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology.
    Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ.
    Cancer Treat Rev. 2012 Feb;38(1):27-35. Epub 2011 Jul 20.
    http://www.ncbi.nlm.nih.gov/pubmed/21764221

  24. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center.
    Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL.
    Anticancer Res. 2011 Jun;31(6):2265-9.
    http://www.ncbi.nlm.nih.gov/pubmed/21737651

  25. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging.
    Hipp SJ, Steffen-Smith E, Hammoud D, Shih JH, Bent R, Warren KE.
    Neuro Oncol. 2011 Aug;13(8):904-9. Epub 2011 Jul 13.
    http://www.ncbi.nlm.nih.gov/pubmed/21757444

  26. Treatment of high-grade glioma in children and adolescents.
    MacDonald TJ, Aguilera D, Kramm CM.
    Neuro Oncol. 2011 Oct;13(10):1049-58. Epub 2011 Jul 22.
    http://www.ncbi.nlm.nih.gov/pubmed/21784756

  27. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
    Chassot A, Canale S, Varlet P, Puget S, Roujeau T, Negretti L, Dhermain F, Rialland X, Raquin MA, Grill J, Dufour C.
    J Neurooncol. 2012 Jan;106(2):399-407. Epub 2011 Aug 20.
    http://www.ncbi.nlm.nih.gov/pubmed/21858607

  28. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.
    Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, Kuttesch J, Ketonen L, Mahajan A.
    J Neurooncol. 2012 Jan;106(2):391-7. Epub 2011 Aug 20.
    http://www.ncbi.nlm.nih.gov/pubmed/21858608

  29. Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.
    Bartels U, Hawkins C, Vézina G, Kun L, Souweidane M, Bouffet E.
    J Neurooncol. 2011 Oct;105(1):119-25. Epub 2011 Sep 8.
    http://www.ncbi.nlm.nih.gov/pubmed/21901544

  30. Shall we treat hydrocephalus associated to brain stem glioma in children?
    Roujeau T, Di Rocco F, Dufour C, Bourdeaut F, Puget S, Rose CS, Zerah M.
    Childs Nerv Syst. 2011 Oct;27(10):1735-9. Epub 2011 Sep 17.
    http://www.ncbi.nlm.nih.gov/pubmed/21928037

  31. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.
    Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ.
    J Clin Oncol. 2011 Oct 20;29(30):3999-4006. Epub 2011 Sep 19.
    http://www.ncbi.nlm.nih.gov/pubmed/21931021

  32. Molecular genetic approaches and potential new therapeutic strategies for pediatric diffuse intrinsic pontine glioma.
    Hawkins CE, Bartels U, Bouffet E.
    J Clin Oncol. 2011 Oct 20;29(30):3956-7. Epub 2011 Sep 19.
    http://www.ncbi.nlm.nih.gov/pubmed/21931033

  33. Genomic aberrations in pediatric diffuse intrinsic pontine gliomas.
    Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS.
    Neuro Oncol. 2011 Nov 7. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22064882

  34. A phase 2 study of pegylated interferon α-2b (PEG-Intron®) in children with diffuse intrinsic pontine glioma.
    Warren K, Bent R, Wolters L, Prager A, Hanson R, Packer R, Shih J, Camphausen K.
    Cancer 2011 Nov 15. doi: 10.1002/cncr.26659. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22086404

  35. Investigating a candidate cell of origin for diffuse intrinsic pontine glioma.
    Mazur MD, Couldwell WT.
    World Neurosurg. 2011 Nov;76(5):368-9.
    http://www.ncbi.nlm.nih.gov/pubmed/22152552

  36. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma.
    Grill J, Puget S, Andreiuolo F, Philippe C, Macconaill L, Kieran MW.
    Pediatr Blood Cancer. 2011 Dec 20. doi: 10.1002/pbc.24060. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22190243

  37. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
    Aoki Y Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N.
    Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, 505 Parnassus Ave., Rm M779, San Francisco, CA, 94143-0112, USA.
    J Neurooncol. 2012 Jan 10. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22231932

  38. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas.
    Li G, Mitra SS, Monje M, Henrich KN, Bangs CD, Nitta RT, Wong AJ.
    Department of Neurosurgery, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA, 94305, USA, gordonli@stanford.edu.
    J Neurooncol. 2012 Mar 2. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/22382786